Literature DB >> 14960142

5: Diagnosis and management of hyperthyroidism and hypothyroidism.

Duncan J Topliss1, Creswell J Eastman.   

Abstract

The most common cause of hyperthyroidism in Australia is Graves disease, caused by a defect in immunoregulation in genetically predisposed individuals, leading to production of thyroid-stimulating antibodies. Each of the three modalities of therapy for Graves disease--thionamide drugs, subtotal or total thyroidectomy, and radioactive iodine ablation--can render the patient euthyroid, but all have potential adverse effects and may not eliminate recurrences. Hypothyroidism occurs in about 5% of the adult population; most present with "subclinical" hypothyroidism (mild thyroid failure), characterised by raised levels of serum thyroid stimulating hormone (TSH) but normal free thyroxine (T(4)). The most common cause of hypothyroidism in Australia is autoimmune chronic lymphocytic thyroiditis, characterised by raised circulating levels of thyroid peroxidase antibody. Symptoms and signs of hypothyroidism are often mild or subtle and, when there is clinical suspicion, thyroid function tests are needed; if serum TSH level is raised, free T(4) and thyroid peroxidase antibody should be measured. Replacement therapy with thyroxine is the cornerstone of therapy (1.6 microg/kg lean body weight daily, taken on an empty stomach); combination therapy with thyroxine and liothyronine (T(3)) is promoted, but there is little evidence of its clinical benefit. Despite the development of highly sensitive laboratory tests, clinical assessment and judgement remain paramount

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14960142     DOI: 10.5694/j.1326-5377.2004.tb05866.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  [Concerning a case of iatrogenic hypothyroidism].

Authors:  J P Justel Pérez; M del Castillo Alemany; I Gil Alós
Journal:  Aten Primaria       Date:  2005-05-31       Impact factor: 1.137

2.  Current concepts in graves' disease.

Authors:  Christian M Girgis; Bernard L Champion; Jack R Wall
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

3.  Identifying a Small Molecule Blocking Antigen Presentation in Autoimmune Thyroiditis.

Authors:  Cheuk Wun Li; Francesca Menconi; Roman Osman; Mihaly Mezei; Eric M Jacobson; Erlinda Concepcion; Chella S David; David B Kastrinsky; Michael Ohlmeyer; Yaron Tomer
Journal:  J Biol Chem       Date:  2015-12-24       Impact factor: 5.157

4.  Resistant thyrotoxicosis in a patient with graves disease: a case report.

Authors:  Taimur Saleem; Aisha Sheikh; Qamar Masood
Journal:  J Thyroid Res       Date:  2011-08-10

5.  The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin.

Authors:  Huy A Tran; Tracey L Jones; Robert G Batey
Journal:  BMC Endocr Disord       Date:  2005-10-12       Impact factor: 2.763

6.  An observational study of the initial management of hypothyroidism in France: the ORCHIDÉE study.

Authors:  Brigitte Delemer; Jean-Pierre Aubert; Pierre Nys; Frédéric Landron; Stéphane Bouée
Journal:  Eur J Endocrinol       Date:  2012-10-03       Impact factor: 6.664

7.  Hypothyroidism in clinical practice.

Authors:  Faiza Qari
Journal:  J Family Med Prim Care       Date:  2014-04

8.  Acute effects of radioiodine therapy on the voice and larynx of Basedow-Graves patients.

Authors:  Roberta Werlang Isolan-Cury; Osmar Monte; Adriano Namo Cury; Marta Assumpção de Andrada E Silva; André Duprat; Marília Marone; Renata de Almeida; Alexandre Iglesias
Journal:  Braz J Otorhinolaryngol       Date:  2008 Mar-Apr
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.